A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

被引:32
作者
Lavigne, Jill E. [1 ]
Heckler, Charles [2 ]
Mathews, Jennifer L. [1 ]
Palesh, Oxana [3 ]
Kirshner, Jeffrey J. [4 ]
Lord, Raymond [4 ]
Jacobs, Andrew [4 ]
Amos, Eric [1 ]
Morrow, Gary R. [2 ]
Mustian, Karen [2 ]
机构
[1] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA
[2] Univ Rochester, Med Ctr, Dept Radiat Oncol, James P Wilmot Canc Ctr, Rochester, NY 14642 USA
[3] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA
[4] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Community Clin Oncol Base, Rochester, NY 14642 USA
关键词
Gabapentin; Neurontin; Anti-epileptics; Breast; Cancer; Anxiety; Randomized controlled trial; Cancer survivorship; PRIMARY-CARE; FOLLOW-UP; PAIN; EFFICACY; MANAGEMENT; DISORDER; BENZODIAZEPINES; MULTICENTER; PREGABALIN; SURGERY;
D O I
10.1007/s10549-012-2251-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 1994, AHCPR PUBLICATION
[2]   Patients' Supportive Care Needs Beyond the End of Cancer Treatment: A Prospective, Longitudinal Survey [J].
Armes, Jo ;
Crowe, Maggie ;
Colbourne, Lynne ;
Morgan, Helen ;
Murrells, Trevor ;
Oakley, Catherine ;
Palmer, Nigel ;
Ream, Emma ;
Young, Annie ;
Richardson, Alison .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6172-6179
[3]   Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis [J].
Baldwin, David ;
Woods, Robert ;
Lawson, Richard ;
Taylor, David .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 342 :637
[4]  
Beaver K., 2009, BMJ, V338, ps3147
[5]   Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study group [J].
Caraceni, A ;
Zecca, E ;
Bonezzi, C ;
Arcuri, E ;
Tur, RY ;
Maltoni, M ;
Visentin, M ;
Gorni, G ;
Martini, C ;
Tirelli, W ;
Barbieri, M ;
De Conno, F .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2909-2917
[6]   Cancer pain assessment in clinical trials. A review of the literature (1999-2002) [J].
Caraceni, A ;
Brunelli, C ;
Martini, C ;
Zecca, E ;
De Conno, F .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 29 (05) :507-519
[7]   An international survey of cancer pain characteristics and syndromes [J].
Caraceni, A ;
Portenoy, RK .
PAIN, 1999, 82 (03) :263-274
[8]   Caring for the Breast Cancer Survivor: A Guide for Primary Care Physicians [J].
Chalasani, Pavani ;
Downey, Leona ;
Stopeck, Alison T. .
AMERICAN JOURNAL OF MEDICINE, 2010, 123 (06) :489-495
[9]  
COLE JO, 1993, J CLIN PSYCHIAT, V54, P49
[10]   XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:: II.: Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys [J].
Cundy, KC ;
Annamalai, T ;
Bu, L ;
De Vera, J ;
Estrela, J ;
Luo, W ;
Shirsat, P ;
Torneros, A ;
Yao, FM ;
Zou, J ;
Barrett, RW ;
Gallop, MA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :324-333